Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FLT3 exon 14 ins FLT3 A627T |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FLT3 exon 14 ins FLT3 A627T | hematologic cancer | predicted - resistant | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing a FLT3-ITD mutation with FLT3 A627T demonstrated resistance to Rydapt (midostaurin) in culture (PMID: 17620426). | 17620426 | |
FLT3 exon 14 ins FLT3 A627T | hematologic cancer | predicted - resistant | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing a FLT3-ITD mutation with FLT3 A627T demonstrated moderate resistance to treatment with Rydapt (midostaurin) in culture (PMID: 15374944). | 15374944 | |
FLT3 exon 14 ins FLT3 A627T | hematologic cancer | predicted - sensitive | PHI-101 | Preclinical - Biochemical | Actionable | In a preclinical study, PHI-101 demonstrated activity against FLT3 A627T in the context of a FLT3-ITD mutation in culture (Cancer Res 2020;80(16 Suppl):Abstract nr 4226). | detail... |